BioXcel Therapeutics (BTAI) Competitors $0.59 -0.01 (-1.67%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BTAI vs. MNPR, NVCT, EPRX, ANIX, KPTI, ELYM, CHRS, IMUX, MNOV, and GBIOShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Monopar Therapeutics (MNPR), Nuvectis Pharma (NVCT), Eupraxia Pharmaceuticals (EPRX), Anixa Biosciences (ANIX), Karyopharm Therapeutics (KPTI), Eliem Therapeutics (ELYM), Coherus BioSciences (CHRS), Immunic (IMUX), MediciNova (MNOV), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Monopar Therapeutics Nuvectis Pharma Eupraxia Pharmaceuticals Anixa Biosciences Karyopharm Therapeutics Eliem Therapeutics Coherus BioSciences Immunic MediciNova Generation Bio BioXcel Therapeutics (NASDAQ:BTAI) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, community ranking, institutional ownership, profitability and dividends. Does the MarketBeat Community prefer BTAI or MNPR? BioXcel Therapeutics received 201 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 72.41% of users gave Monopar Therapeutics an outperform vote while only 67.50% of users gave BioXcel Therapeutics an outperform vote. CompanyUnderperformOutperformBioXcel TherapeuticsOutperform Votes24367.50% Underperform Votes11732.50% Monopar TherapeuticsOutperform Votes4272.41% Underperform Votes1627.59% Is BTAI or MNPR more profitable? Monopar Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -3,119.33%. BioXcel Therapeutics' return on equity of 0.00% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-3,119.33% N/A -105.04% Monopar Therapeutics N/A -107.21%-87.57% Which has preferable valuation and earnings, BTAI or MNPR? Monopar Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$1.38M18.22-$179.05M-$2.16-0.27Monopar TherapeuticsN/AN/A-$8.40M-$1.97-9.64 Which has more volatility & risk, BTAI or MNPR? BioXcel Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Do institutionals & insiders hold more shares of BTAI or MNPR? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 28.7% of BioXcel Therapeutics shares are held by insiders. Comparatively, 34.9% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer BTAI or MNPR? In the previous week, Monopar Therapeutics had 2 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 4 mentions for BioXcel Therapeutics. Monopar Therapeutics' average media sentiment score of 1.00 beat BioXcel Therapeutics' score of 0.25 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer BTAI or MNPR? BioXcel Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 750.34%. Monopar Therapeutics has a consensus price target of $27.33, suggesting a potential upside of 43.86%. Given BioXcel Therapeutics' higher probable upside, research analysts clearly believe BioXcel Therapeutics is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Monopar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMonopar Therapeutics beats BioXcel Therapeutics on 10 of the 16 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.14M$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-0.2710.78135.4117.82Price / Sales18.22243.751,160.9774.56Price / CashN/A22.1633.5332.53Price / Book-0.315.474.674.68Net Income-$179.05M$153.61M$119.07M$226.08M7 Day Performance12.99%-2.00%-1.83%-1.04%1 Month Performance7.06%-7.46%-3.60%1.04%1 Year Performance-84.92%31.82%31.66%26.28% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.5124 of 5 stars$0.59-1.7%$5.00+750.3%-84.6%$25.14M$1.38M-0.2790Gap DownMNPRMonopar Therapeutics3.5846 of 5 stars$19.00-0.1%$27.33+43.9%+1,213.5%$100.33MN/A0.0010Gap UpNVCTNuvectis Pharma3.2986 of 5 stars$5.07-1.4%$21.00+314.2%-38.8%$99.31MN/A0.008EPRXEupraxia Pharmaceuticals2.4867 of 5 stars$3.62+11.0%$9.00+148.6%N/A$98.75MN/A-5.0329Gap UpHigh Trading VolumeANIXAnixa Biosciences2.8707 of 5 stars$3.05-2.6%$7.00+129.9%+2.9%$97.99M$210,000.00-7.815Analyst ForecastNews CoverageKPTIKaryopharm Therapeutics3.9896 of 5 stars$0.78flat$5.00+545.2%-1.5%$96.87M$146.03M0.00380ELYMEliem TherapeuticsN/A$3.25+6.2%N/A+28.0%$96.69MN/A-6.1320CHRSCoherus BioSciences3.8225 of 5 stars$1.10+34.1%$6.13+456.8%-46.9%$94.65M$304.34M-13.75246High Trading VolumeIMUXImmunic3.0869 of 5 stars$1.07+1.9%$12.25+1,044.9%-3.6%$94.58MN/A0.0070MNOVMediciNova0.668 of 5 stars$1.95+2.6%N/A-5.3%$93.19M$1M0.0010News CoverageGap UpGBIOGeneration Bio3.359 of 5 stars$1.35-2.9%$7.50+455.6%+7.1%$92.84M$5.90M0.00150 Related Companies and Tools Related Companies Monopar Therapeutics Alternatives Nuvectis Pharma Alternatives Eupraxia Pharmaceuticals Alternatives Anixa Biosciences Alternatives Karyopharm Therapeutics Alternatives Eliem Therapeutics Alternatives Coherus BioSciences Alternatives Immunic Alternatives MediciNova Alternatives Generation Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BTAI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTAI Stock Alerts